<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107229</article-id><article-id pub-id-type="publisher-id">ACM-36809</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_24805958.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  抗血小板治疗在缺血性脑卒中的研究进展
  Progress of Antiplatelet Therapy in Ischemic Stroke
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>喜斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>康</surname><given-names>乐乐</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>学军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院神经内科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1531</fpage><lpage>1536</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    缺血性脑卒中系由各种原因所致的局部脑组织区域血液供应障碍，导致脑组织缺血缺氧性病变坏死，进而产生临床上对应的神经功能缺失表现，严重影响着患者的生存质量。抗血小板治疗能够降低缺血性脑卒中的早期复发率、早期死亡率，并能改善患者长期预后。本文将对缺血性脑卒中常用抗血小板药物的作用机制及药物特征进行综述。
    Ischemic stroke is caused by various causes of regional blood supply disorders in brain tissue, resulting in ischemic hypoxic lesions necrosis of brain tissue, and then produce clinical corresponding neurological deficit manifestations, seriously affecting the quality of life of patients. Antiplatelet therapy can reduce the early recurrence rate, early mortality rate and improve the long-term prognosis of patients with ischemic stroke. This article will review the mechanism and characteristics of commonly used antiplatelet drugs in ischemic stroke. 
  
 
</p></abstract><kwd-group><kwd>抗血小板，缺血性脑卒中, Antiplatelet</kwd><kwd> Ischemic Stroke</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>抗血小板治疗在缺血性脑卒中的研究进展<sup> </sup></title><p>高喜斌，康乐乐，高学军<sup>*</sup></p><p>延安大学附属医院神经内科，陕西 延安</p><p>收稿日期：2020年7月13日；录用日期：2020年7月23日；发布日期：2020年7月30日</p><disp-formula id="hanspub.36809-formula80"><graphic xlink:href="//html.hanspub.org/file/55-1571388x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>缺血性脑卒中系由各种原因所致的局部脑组织区域血液供应障碍，导致脑组织缺血缺氧性病变坏死，进而产生临床上对应的神经功能缺失表现，严重影响着患者的生存质量。抗血小板治疗能够降低缺血性脑卒中的早期复发率、早期死亡率，并能改善患者长期预后。本文将对缺血性脑卒中常用抗血小板药物的作用机制及药物特征进行综述。</p><p>关键词 :抗血小板，缺血性脑卒中</p><disp-formula id="hanspub.36809-formula81"><graphic xlink:href="//html.hanspub.org/file/55-1571388x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/55-1571388x8_hanspub.png" /> <img src="//html.hanspub.org/file/55-1571388x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>缺血性脑卒中是一种相对常见的疾病，严重威胁人类健康,其发病率在全球范围内呈上升趋势，发病率、死亡率和致残率都很高 [<xref ref-type="bibr" rid="hanspub.36809-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref5">5</xref>]。当代社会压力越来越大及不健康的生活方式导致年轻人脑梗死发病率增加，对家庭和整个社会都产生负面影响 [<xref ref-type="bibr" rid="hanspub.36809-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref8">8</xref>]，对家庭和整个社会都产生负面影响 [<xref ref-type="bibr" rid="hanspub.36809-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref9">9</xref>]。中国疾控中心2014年发布的一份情况说明书显示，中国的脑梗死发病率几乎是世界上最高的，脑血管病自2008年以来一直位列中国主要死因之列 [<xref ref-type="bibr" rid="hanspub.36809-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref11">11</xref>]，已成为仅次于恶性肿瘤和心脏病的第三大死因。系统分析估计，中国每年约有17亿患者死于脑梗死，存活个体的复发率超过17.1% [<xref ref-type="bibr" rid="hanspub.36809-ref9">9</xref>]。缺血性脑卒中治疗的关键是挽救缺血性脑组织，包括溶栓、桥接取栓恢复脑血流灌注，但大多数患者到院时已经错过治疗时间。因此，抗血小板聚集治疗在缺血性脑卒中中治疗至关重要。抗血小板治疗用于急性缺血性脑卒中的治疗和脑卒中的预防。抗血小板治疗可降低动脉粥样硬化高危患者和已知有脑血管疾病症状的患者的卒中发生率。</p></sec><sec id="s4"><title>2. 缺血性脑卒中时血小板的作用</title><p>缺血性脑卒中是由脑血栓形成、栓塞或其他原因引起的脑功能不全的疾病。本病多发于中老年人，可对中枢神经系统造成严重损害有效和及时的治疗是降低这种疾病造成的死亡率和残疾的关键。当血管内皮受损时，激活血小板和凝血酶，活化的血小板进一步激活更多的血小板，并表达组织因子，产生促凝作用，并形成凝血酶。在血液循环中。凝血酶使纤维蛋白原形成纤维蛋白，进而形成血凝块，从而使得血栓生成堵塞血管。因此抑制血小板可有效减少缺血性脑卒中事件的发生，有效的血小板治疗对缺血性脑卒中至关重要,本文将对临床上常见的抗血小板药物进行论述。</p></sec><sec id="s5"><title>3. 常见的抗血小板药物及研究进展</title><sec id="s5_1"><title>3.1. 阿司匹林</title><p>阿司匹林是一种乙酰水杨酸，属于非甾体抗炎药(NSAIDs)。这些药物减少了炎症的迹象和症状，并表现出广泛的药理作用，包括止痛、解热和抗血小板特性。1899年，拜耳(Bayer)公司首次推出阿司匹林。阿司匹林和其他非甾体抗炎药在用于缓解症状的情况下通常不会改变疾病的进程。低剂量阿司匹林(100~150 mg)不可逆的抑制乙酰化环氧合酶(COX)-1的530位丝氨酸。这种作用抑制血小板生成的血栓素A2，从而产生抗血栓作用。</p><p>阿司匹林是一种有效的药物血小板聚集抑制剂及其抗血栓作用主要是由于乙酰化环氧合酶(COX1)的不可逆抑制，而COX1又抑制血小板中前列腺素H2 (PGH2)的生成。阿司匹林还抑制血管内皮细胞中的PG合酶，导致PGI2生成减少，部分抵消了其抗血栓作用。尽管阿司匹林、氯吡格雷和阿司匹林–缓释双嘧达莫复方制剂治疗对于脑卒中二级预防都是可以接受的选择，但阿司匹林是唯一已确定对急性缺血性脑卒中极早期治疗有效的抗血小板药物 [<xref ref-type="bibr" rid="hanspub.36809-ref12">12</xref>]。一项2014年的抗血小板治疗急性脑卒中得出结论，在假定缺血性脑卒中发作的48小时内开始使用阿司匹林(160~300 mg/d)，降低了早期复发性缺血性脑卒中的风险，并且没有早期出血性并发症的重大风险，还改善了长期结局。对于基线时存在轻度和中度脑卒中相关神经功能障碍的患者，阿司匹林降低了复发缺血性脑卒中的风险，但重度神经功能障碍患者未见此效应 [<xref ref-type="bibr" rid="hanspub.36809-ref13">13</xref>]。对于轻度和中度神经功能障碍患者，到开始阿司匹林治疗后第3日，风险降低最显著。我国缺血性脑卒中诊治指南也推荐 [<xref ref-type="bibr" rid="hanspub.36809-ref14">14</xref>]，对于不符合静脉溶栓或血管内取栓适应症的缺血性脑卒中患者应在发病后尽早给予口服阿司匹林150~300 mg/d治疗，急性期后可改为预防剂量50~300 mg/d。</p><p>阿司匹林最长见的不良反应是胃肠道出血，其他不良反应还包括头痛、眩晕、耳鸣、恶心、皮下瘀斑和颅内出血等。由于使用阿司匹林可能出现支气管痉挛、血管神经性水肿或尿路感染及Ｒeye综合征，对非甾体类抗炎药过敏以及哮喘、鼻炎和鼻息肉的患者或患有病毒感染的儿童和年轻人禁用阿司匹林 [<xref ref-type="bibr" rid="hanspub.36809-ref15">15</xref>]。</p></sec><sec id="s5_2"><title>3.2. 氯吡格雷</title><p>氯吡格雷是另一种抗血小板药物，与阿司匹林的作用机制不同，是一种血小板P2Y12受体阻滞剂，其代谢产物通过二硫键与血小板表面的P2Y12编码的ADP受体特异性、不可逆性结合，阻断ADP对腺苷酸环化酶的抑制作用，达到抑制血小板聚集的作用 [<xref ref-type="bibr" rid="hanspub.36809-ref16">16</xref>]。研究表明，在治疗开始后1 d内，当患者计划进行血管内再通时，常常给予300或600 mg的负荷剂量以加速发挥其抗血小板作用 [<xref ref-type="bibr" rid="hanspub.36809-ref17">17</xref>]，对高危患者，氯吡格雷预防效果可能更明显，不良反应更少 [<xref ref-type="bibr" rid="hanspub.36809-ref18">18</xref>]。阿司匹林、氯吡格雷和阿司匹与氯吡格雷–联合用药是目前推荐用于心脑血管缺血事件二级预防的唯一抗血栓药物 [<xref ref-type="bibr" rid="hanspub.36809-ref19">19</xref>]。双重抗血小板方案可以相对减少中风，但长期使用可能会导致全身出血事件 [<xref ref-type="bibr" rid="hanspub.36809-ref19">19</xref>]。</p><p>然而不幸的是，并不是所有患者对氯吡格雷具有良好的反应，部分患者存在抵抗现象，并且有研究认为，CYP2C19是氯吡格雷抵抗的独立预测因素 [<xref ref-type="bibr" rid="hanspub.36809-ref20">20</xref>]。Gu等 [<xref ref-type="bibr" rid="hanspub.36809-ref21">21</xref>] 也证实，CYP2C19 基因多态性与缺血性脑卒中的发生及复发有关。氯吡格雷治疗失败的最佳定义是在氯吡格雷治疗高血小板反应性的患者期间发生血栓事件/缺血性事件。治疗失败可能是由于病人不服从和/或对氯吡格雷的抗血小板作用反应不充分。由于多个信号通路介导血小板活化和血栓事件的发生，不能指望针对单一通路的治疗策略可以预防所有事件的发生。因此，并不是所有服用氯吡格雷的患者的缺血性事件都是由于缺乏氯吡格雷的药效学效应。血栓事件的发生涉及多种机制。这些机制可能克服氯吡格雷的药效学效应。</p><p>与阿司匹林相比，氯吡格雷的副反应较好，出现皮疹和腹泻的频率略高，但出现胃不适或消化道出血的频率略低 [<xref ref-type="bibr" rid="hanspub.36809-ref22">22</xref>]。</p></sec><sec id="s5_3"><title>3.3. 其他抗血小板药物</title><p>双嘧达莫抑制血液循环中红细胞和血管内皮对腺苷的摄取和代谢作用，从而使腺苷在血管内皮内浓度增加。腺苷酸环化酶被激活，血液中环磷酸腺苷浓度升高，抑制血小板聚集功能增强。阿司匹林、氯吡格雷和阿司匹林缓释片双嘧达莫之间的选择主要取决于患者的耐受性、禁忌症、可用性和成本。这三种方法都是可接受的预防复发性非心源性缺血性卒中的方法 [<xref ref-type="bibr" rid="hanspub.36809-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref25">25</xref>]。建议抗血小板治疗使用氯吡格雷(75毫克每天)作为单一疗法或联合阿司匹林缓释双嘧达莫(25毫克/200毫克每天两次)，而不是单独使用阿司匹林 [<xref ref-type="bibr" rid="hanspub.36809-ref23">23</xref>]。与阿司匹林用于严重血管事件的长期二级预防(即非致死性中风、非致死性心肌梗死或血管死亡)相比，单独使用氯吡格雷和使用阿司匹林缓释双嘧达莫 [<xref ref-type="bibr" rid="hanspub.36809-ref25">25</xref>] 的益处似乎要大一些。</p><p>阿司匹林加双嘧达莫已在多个试验中被证明在二次中风预防中有效，尽管早期的结果并没有显示出单独阿司匹林的任何有益作用 [<xref ref-type="bibr" rid="hanspub.36809-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.36809-ref28">28</xref>]。“第二次欧洲卒中预防研究” [<xref ref-type="bibr" rid="hanspub.36809-ref27">27</xref>] 和可逆性脑缺血试验 [<xref ref-type="bibr" rid="hanspub.36809-ref28">28</xref>] 中的欧洲和澳大利亚卒中预防研究表明，阿司匹林中联合双嘧达莫可显著降低卒中复发率。双嘧达莫联合阿司匹林与单用阿司匹林在短暂性脑缺血发作或脑卒中后二级预防中的荟萃分析也表明，双嘧达莫联合阿司匹林显著降低了先前短暂性脑缺血或缺血性脑卒中患者脑卒中的复发率 [<xref ref-type="bibr" rid="hanspub.36809-ref26">26</xref>]。使用双嘧达莫应警惕其不良反应，常见的不良反应有腹泻、头痛、贫血及消化道出血等。</p><p>与氯吡格雷类似，替格瑞洛通过抑制P2Y12受体，可阻断二磷酸腺苷与特定血小板受体P2Y12的结合，从而抑制糖蛋白(GP) IIb/IIIa复合物的激活和血小板聚集 [<xref ref-type="bibr" rid="hanspub.36809-ref29">29</xref>]。</p><p>与上述抗血小板药物相比，替格瑞洛具有一些新型而有效的抗血栓特性。替格瑞洛是唯一一种可逆阻断ADP受体的噻吩吡啶，通过ENT-1抑制作用增加血液循环中腺苷水平，从而发挥生物效应，包括血小板抑制、血管舒张、炎症环境的调节以及对缺血或再灌注损伤的保护 [<xref ref-type="bibr" rid="hanspub.36809-ref30">30</xref>]。动物IS模型已经证明替格瑞洛除了抗血小板特性外还有神经保护作用 [<xref ref-type="bibr" rid="hanspub.36809-ref31">31</xref>]。最近，苏格拉底试验的一个亚组分析证实了这些益处，即在伴有同侧潜在症状性动脉粥样硬化狭窄的轻度IS或高风险TIA患者中，相对风险降低30%以上 [<xref ref-type="bibr" rid="hanspub.36809-ref32">32</xref>]。由于五分之一的缺血性中风由目前使用的抗血栓治疗方案中的动脉粥样硬化血栓事件组成 [<xref ref-type="bibr" rid="hanspub.36809-ref33">33</xref>]，替格瑞洛似乎是二级预防中风的更有效的抗血栓治疗方案，特别是在高危IS患者亚组中。相反，最近的AHA/ASA指南并不推荐替格瑞洛而不是阿司匹林用于轻度中风(NIHSS ≤ 5)或高风险TIA患者的急性治疗，因为对复合性中风、MI或死亡的主要结果缺乏优势。虽然替格瑞洛对轻型卒中的疗效并不优于阿司匹林，但替格瑞洛似乎是对有阿司匹林禁忌症(III类证据)的卒中患者的合理选择 [<xref ref-type="bibr" rid="hanspub.36809-ref33">33</xref>]。此外，卒中复发后更换抗血栓药物是一种常见的做法，为随后的有效抗血栓治疗提出了治疗难题。先前的观察研究已经评估了抗血栓药物，包括氯吡格雷 [<xref ref-type="bibr" rid="hanspub.36809-ref34">34</xref>]，并评估了转用替格瑞洛的临床结果。这些研究得出结论，替格瑞洛具有更高水平的血小板抑制作用，并且在噻吩吡啶无应答者中具有类似的疗效。然而，在最近轻度急性缺血性卒中(AIS)或短暂性脑缺血发作(TIA) [<xref ref-type="bibr" rid="hanspub.36809-ref35">35</xref>] 患者的RCT中，在减少心血管事件方面，替格瑞洛没有优于阿司匹林或氯吡格雷单一疗法。值得注意的是，随后对阿司匹林或替格瑞洛治疗的急性中风或短暂性缺血发作进行的探索性分析和患者预后试验 [<xref ref-type="bibr" rid="hanspub.36809-ref32">32</xref>] 表明，与阿司匹林相比，替格瑞洛在AIS/TIA大动脉粥样硬化患者亚群中的优势。上述研究提示，动脉粥样硬化性脑卒中患者可能获益于除阿司匹林外的其他抗血小板治疗。此外，替格瑞洛对反复中风和复合性中风/心肌梗死/心血管病的二级预防仍有良好的疗效。替格瑞洛没有增加脑出血的风险，全因死亡率，或重大出血事件。Konark等 [<xref ref-type="bibr" rid="hanspub.36809-ref36">36</xref>] 研究表明替格瑞洛似乎是脑或心血管危险因素患者一级和二级预防中风的有益选择。需要进一步的随机对照试验来评估替格瑞洛在二次中风预防中的作用。</p></sec></sec><sec id="s6"><title>4. 总结</title><p>全世界目前脑卒中防治形势严峻，抗血小板药物在缺血性脑卒中的作用举足轻重。缺血性脑卒中多发于中老年人，可对中枢神经系统造成严重损害。脑梗死具有高死亡率和高发病率的特点，全世界每年约有550万人死于脑梗死。由于中国人口生活水平的提高和老龄化，脑梗死患者的数量有所增加。有效及时的治疗是降低该病死亡率和致残率的关键。目前用于治疗的方法是迅速恢复缺血脑组织的血液供应，最有希望的治疗方法是溶栓药物，但溶栓时间通常很短，因此抗血小板聚集治疗在缺血性脑卒中的治疗至关重要。然而，抗血小板药物也是一把“双刃剑”，在使用时需要严格掌握药物的适应症及禁忌症，以免发生出血等不良反应。目前抗血小板药物仍具有起效慢、反应差、撤药慢等特性。因此，在今后的研究中关于抗血小板治疗仍要不断探索，研发更为理想的抗血小板药物，为防治脑卒中提供更为专一的抗血小板治疗方案，使脑卒中患者得到更大的获益。</p></sec><sec id="s7"><title>文章引用</title><p>高喜斌,康乐乐,高学军. 抗血小板治疗在缺血性脑卒中的研究进展Progress of Antiplatelet Therapy in Ischemic Stroke[J]. 临床医学进展, 2020, 10(07): 1531-1536. https://doi.org/10.12677/ACM.2020.107229</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36809-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bielewicz, J., Kurzepa, J., Lagowska-Lenard, M., et al. (2010) The Novel Views on the Pathomechanism of Ischemic Stroke. Wiadomosci Lekarskie, 63, 213-220.</mixed-citation></ref><ref id="hanspub.36809-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y. (2010) To Prevent and Treat Stroke Completely and Systematically and Reduce Its Damages. Shanghai Medical Journal, 9, 793-794.</mixed-citation></ref><ref id="hanspub.36809-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H. and Cai, H. (2015) The Clinical Curative Effect Observation of Treating Acute Cerebral Infarction in the Very Early Stage with Acupuncture. Journal of Clinical Acupuncture and Moxibustion, 3, 31-32.</mixed-citation></ref><ref id="hanspub.36809-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Murray, C.J. and Lopez, A.D. (2013) Measuring the Global Burden of Disease. The New England Journal of Medicine, 369, 448-457. &lt;br&gt;https://doi.org/10.1056/NEJMra1201534</mixed-citation></ref><ref id="hanspub.36809-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yu, C., Luo, L., Li, M., et al. (2016) To Observe the Heavy Burden of Stroke in China from the View of the World. J Public Health Prev Med, 1, 1-5.</mixed-citation></ref><ref id="hanspub.36809-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Liu, S. (2007) Analysis about the Effects of Treating Stroke with Hyperbaric Oxygen and the Related Sequela. Chinese Journal of Practical Internal Medicine, S1, 256-267.</mixed-citation></ref><ref id="hanspub.36809-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y. (2011) Analysis about Prevention Measures for Stroke. Chinese Journal of Practical Nervous Diseases, 1, 52-53.</mixed-citation></ref><ref id="hanspub.36809-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gong, L. (2005) The Recent Situation of Researches about the Young Stroke. China Med Abstr., 2, 237-239.</mixed-citation></ref><ref id="hanspub.36809-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yang, G., Wang, Y., Zeng, Y., et al. (2013) Rapid Health Transition in China, 1990-2010: Findings from the Global Burden of Disease Study 2010. The Lancet, 381, 1987-2015. &lt;br&gt;https://doi.org/10.1016/S0140-6736(13)61097-1</mixed-citation></ref><ref id="hanspub.36809-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ministry of Health of the PRC (2008) The Main Conditions of the Third Time National Death Inquiry. China Cancer, 5, 344-345.</mixed-citation></ref><ref id="hanspub.36809-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Wu, S., Gao, J., et al. (2012) The Influence of Ideal Cardiovascular Healthy Behaviors and Factors for New Ischemic Stroke. Chinese Journal of Hypertension, 4, 342-346.</mixed-citation></ref><ref id="hanspub.36809-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sandercock, P.A., Counsell, C., Tseng, M.C. and Cecconi, E. (2014) Oral Antiplatelet Therapy for Acute Ischaemic Stroke. Cochrane Database of Systematic Reviews, 3, CD000029. &lt;br&gt;https://doi.org/10.1002/14651858.CD000029.pub3</mixed-citation></ref><ref id="hanspub.36809-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Rothwell, P.M., Algra, A., Chen, Z., et al. (2016) Effects of Aspirin on Risk and Severity of Early Recurrent Stroke after Transient Ischaemic Attack and Ischaemic Stroke: Time-Course Analysis of Randomised Trials. The Lancet, 388, 365. &lt;br&gt;https://doi.org/10.1016/S0140-6736(16)30468-8</mixed-citation></ref><ref id="hanspub.36809-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682.</mixed-citation></ref><ref id="hanspub.36809-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Laine, M., Paganelli, F. and Bonello, L. (2016) P2Y12-ADP Receptor Antagonists: Days of Future and Past. World Journal of Cardiology, 8, 327. &lt;br&gt;https://doi.org/10.4330/wjc.v8.i5.327</mixed-citation></ref><ref id="hanspub.36809-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Scott, S.A., Sangkuhl, K., Gardner, E.E., et al. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genoty Peandclopidogrel Therapy. Clinical Pharmacology &amp; Therapeutics, 90, 328-332. &lt;br&gt;https://doi.org/10.1038/clpt.2011.132</mixed-citation></ref><ref id="hanspub.36809-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Meschia, J.F., Bushnell, C., Boden-Albala, B., et al. (2014) Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 45, 3754-3832. &lt;br&gt;https://doi.org/10.1161/STR.0000000000000046</mixed-citation></ref><ref id="hanspub.36809-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lee, M., Saver, J.L., Hong, K.S., et al. (2013) Risk-Benefit Profile of Long-Term Dual- versus Single-Antiplatelet Therapy among Patients with Ischemic Stroke: A Systematic Review and Meta-Analysis. Annals of Internal Medicine, 159, 463-470. &lt;br&gt;https://doi.org/10.7326/0003-4819-159-7-201310010-00006</mixed-citation></ref><ref id="hanspub.36809-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kernan, W.N., Ovbiagele, B., Black, H.R., et al. (2014) Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160-2236. &lt;br&gt;https://doi.org/10.1161/STR.0000000000000024</mixed-citation></ref><ref id="hanspub.36809-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Jia, D.M., Chen, Z.B., Zhang, M.J., et al. (2013) CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China. Stroke, 44, 1717-1719. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.113.000823</mixed-citation></ref><ref id="hanspub.36809-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gu, S., Sun, Y., Han, R., et al. (2014) Association between Genetic Polymorphisms of Cytochrome P450 2C19 and the Risk of Cerebral Ischemic Stroke in Chinese. BMC Medical Genetics, 15, 83. &lt;br&gt;https://doi.org/10.1186/1471-2350-15-83</mixed-citation></ref><ref id="hanspub.36809-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Serebruany, V.L., Steinhubl, S.R., Berger, P.B., et al. (2005) Analysis of Risk of Bleeding Complications after Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. American Journal of Cardiology, 95, 1218. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2005.01.049</mixed-citation></ref><ref id="hanspub.36809-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Lansberg, M.G., O’Donnell, M.J., Khatri, P., et al. (2012) Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e601S. &lt;br&gt;https://doi.org/10.1378/chest.141.4.1129b</mixed-citation></ref><ref id="hanspub.36809-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">(2014) Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160.  
&lt;br&gt;https://doi.org/10.1161/STR.0000000000000024</mixed-citation></ref><ref id="hanspub.36809-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Greving, J.P., Diener, H.C., Reitsma, J.B., et al. (2019) Antiplatelet Therapy after Noncardioembolic Stroke. Stroke, 50, 1812. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.118.024497</mixed-citation></ref><ref id="hanspub.36809-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Halkes, P.H., Gray, L.J., Bath, P.M., et al. (2008) Dipyridamole plus Aspirin versus Aspirin Alone in Secondary Prevention after TIA Orstroke: A Meta-Analysis by Risk. Journal of Neurology, Neurosurgery and Psychiatry, 79, 1218- 1223. &lt;br&gt;https://doi.org/10.1136/jnnp.2008.143875</mixed-citation></ref><ref id="hanspub.36809-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Diener, H.C., Cunha, L., Forbes, C., et al. (1996) European Stroke Prevention Study. 2. Dipyridamole and Acetylsalicylic Acid in the Secondary Prevention of Stroke. Journal of the Neurological Sciences, 14, 1-13.  
&lt;br&gt;https://doi.org/10.1016/S0022-510X(96)00308-5</mixed-citation></ref><ref id="hanspub.36809-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Halkes, P.H., van Gijn, J., Kappelle, L.J., et al. (2006) Aspirin plus Dipyridamole versus Aspirin Alone after Cerebral Ischaemia of Arterial Origin (ESPRIT): Randomised Controlled Trial. The Lancet, 367, 1665-1673.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(06)68734-5</mixed-citation></ref><ref id="hanspub.36809-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Foster, C.J., Prosser, D.M., Agans, J.M., et al. (2001) Molecular Identification and Characterization of the Platelet ADP Receptor Targeted by Thienopyridine Antithrombotic Drugs. Journal of Clinical Investigation, 107, 1591.  
&lt;br&gt;https://doi.org/10.1172/JCI12242</mixed-citation></ref><ref id="hanspub.36809-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Cattaneo, M., Schulz, R. and Nylander, S. (2014) Adenosine-Mediated Effects of Ticagrelor: Evidence and Potential Clinical Relevance. Journal of the American College of Cardiology, 63, 2503-2509.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2014.03.031</mixed-citation></ref><ref id="hanspub.36809-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Yamauchi, K., Imai, T., Shimazawa, M., et al. (2017) Effects of Ticagrelor in Amouse Model of Ischemic Stroke. Scientific Reports, 7, Article No. 12088. &lt;br&gt;https://doi.org/10.1038/s41598-017-12205-w</mixed-citation></ref><ref id="hanspub.36809-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Amarenco, P., Albers, G.W., Denison, H., et al. (2017) Efficacy and Safety of Ticagrelor versus Aspirin in Acute Stroke or Transient Ischaemic Attack of Atherosclerotic Origin: A Subgroup Analysis of SOCRATES, a Randomised, Double-Blind, Controlled Trial. The Lancet Neurology, 16, 301-310. &lt;br&gt;https://doi.org/10.1016/S1474-4422(17)30038-8</mixed-citation></ref><ref id="hanspub.36809-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Malhotra, K., Goyal, N. and Tsivgoulis, G. (2017) Internal Carotid Artery Occlusion: Pathophysiology, Diagnosis, and Management. Current Atherosclerosis Reports, 19, 41. &lt;br&gt;https://doi.org/10.1007/s11883-017-0677-7</mixed-citation></ref><ref id="hanspub.36809-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Powers, W.J., Rabinstein, A.A., Ackerson, T., et al. (2018) 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 49, e46-e110.</mixed-citation></ref><ref id="hanspub.36809-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Johnston, S.C., Amarenco, P., Albers, G.W., et al. (2016) Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. The New England Journal of Medicine, 375, 35-43. &lt;br&gt;https://doi.org/10.1056/NEJMoa1603060</mixed-citation></ref><ref id="hanspub.36809-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Konark, M., Nitin, G., Alissa, S., et al. (2018) Ticagrelor for Stroke Prevention in Patients with Vascular Risk Factors: A Systematic Review and Meta-Analysis. Journal of the Neurological Sciences, 390, 212-218.  
&lt;br&gt;https://doi.org/10.1016/j.jns.2018.05.001</mixed-citation></ref></ref-list></back></article>